A number of preclinical studies in cancer have reported that YM155 effectively inhibits survivin expression and consequently reduces cell proliferation, increases apoptosis, and sensitizes cells to cytotoxic genes and radiotherapy (Nakahara et al., 2007; Tao et al., 2012). The gene discussed is BIRC5; the disease is cancer.